RHYTHM PHARMACEUTICALS

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

22 May 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

08 May 2023 08:00:08 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

05 May 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

10 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 Apr 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

27 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

01 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

27 Feb 2023 08:45:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

23 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

05 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

07 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference

01 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

21 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

08 Nov 2022 07:05:00 By Nasdaq GlobeNewswire